The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - Lilly
 
Andrew Koff
No Relationships to Disclose
 
Sandra P. D'Angelo
Consulting or Advisory Role - Amgen; EMD Serono; GlaxoSmithKline; Immune design; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Patents, Royalties, Other Intellectual Property - Phase II study of TVEC + pembrolizumab in sarcoma
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
 
Mrinal M. Gounder
Honoraria - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TRACON Pharma
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Other Relationship - Desmoid Tumor Research Foundation
 
Mary Louise Keohan
No Relationships to Disclose
 
Ciara Marie Kelly
Research Funding - AGIOS (Inst); Amgen (Inst); INCYTE (Inst); Merck (Inst)
 
Ping Chi
Employment - Pfizer (I)
Honoraria - Novartis
Consulting or Advisory Role - Deciphera
Research Funding - Novartis (Inst); Novartis (Inst)
 
Cristina R. Antonescu
No Relationships to Disclose
 
Jonathan Landa
No Relationships to Disclose
 
Li-Xuan Qin
Employment - MedImmune (I); Viela Bio (I)
Leadership - Viela Bio (I)
Stock and Other Ownership Interests - Viela Bio (I)
 
Aimee Marie Crago
Patents, Royalties, Other Intellectual Property - Patent assigned to MSKCC for a companion diagnostic to CDK4 inhibitors - Patent number 9,889,135 (Inst)
 
Samuel Singer
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625